Oruka Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Oruka Therapeutics, Inc. (ORKA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$2.29 million for the 3-month period ending 2012-06-30, per its 10-Q filed 2012-08-13.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2012-08-13
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2012-06-30 was -$2.29M, a 879.59% decline year-over-year.
- Oruka Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2011-06-30 was $294.00K.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month |
|---|---|---|
| 2012-06-30 | -$2.29M 10-Q · filed 2012-08-13 | -$2.55M 10-Q · filed 2012-08-13 |
| 2011-06-30 | $294.00K 10-Q · filed 2012-08-13 | -$1.91M 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |